E

Editas Medicine

D
EDIT
USD
0.05
(1.292%)
Market Closed
78,291.00
Volume
-3.125
EPS
-
Div Yield
-1.682403
P/E
323,307,629.12
Market Cap
Today
1.2920%
1 Week
4.673%
1 Month
-4.623%
6 Months
-49.354%
12 Months
-50.939%
Year To Date
-61.265%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
C
CRSP
-0.11
(-0.2219%)
USD
N
NTLA
0.41
(1.8214%)
USD
S
SGMO
0.0617
(7.3584%)
USD
B
BLUE
-0.0046
(-0.9287%)
USD
T
TDOC
0.065
(0.7135%)
USD
V
VCEL
1.62
(3.4921%)
USD
R
RGNX
-0.043
(-0.3429%)
USD
REGN
REGN
11.33
(0.9948%)
USD
B
BMRN
0.31
(0.4359%)
USD
A
ARWR
0.35
(1.6851%)
USD

Title:
Editas Medicine

Sector:
Healthcare
Industry:
Biotechnology
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Do you need help or have a question?
Contact Us